



Standing Way Eaglestone Milton Keynes MK6 5LD 01908 660033 www.mkuh.nhs.uk

## Request under Freedom of Information Act 2000

I am pleased to confirm the following.

1. Does your trust use the following biosimilar biologic therapies, and if possible how many patients are currently being treated?

Adalimumab [Hyrimoz]	No
Adalimumab [Amgevita]	Yes - 1
Adalimumab [Imraldi]	Yes - 190
Adalimumab [Hulio]	No
Etanercept [Benepali]	Yes - 36
Etanercept [Erelzi]	No
Infliximab [Inflectra]	No
Infliximab [Remsima]	No
Infliximab [Flixabi]	No

2. Within your rheumatology department;

a. how many patients in the year 2018 were treated with a biologic or JAK2 179 b. how many patients in the year 2018 were treated with a DMARD [for example azathioprine, ciclosporin, methotrexate, hydroxychloroquine, leflunomide, sulfasalazine or minocycline]. The Trust does not record information this information.

## 3. Within your dermatology department;

a. how many patients in the year 2018 were treated with a biologic or JAK2 25
b. how many patients in the year 2018 were treated with a DMARD [for example azathioprine, ciclosporin, methotrexate, hydroxychloroquine, leflunomide, sulfasalazine or minocycline] The Trust does not record this information.

4. Within your gastrenterology department;

a. how many patients in the year 2018 were treated with a biologic or JAK2 72
 b. how many patients in the year 2018 were treated with a DMARD [for example azathioprine, ciclosporin, methotrexate, hydroxychloroquine, leflunomide, sulfasalazine or minocycline] The Trust does not record this information.

## 5. Does your trust record the DAS score electronically on the patient records? If so how many are DAS 5+

The Trust does not record this information in a central location. To obtain this information would entail trawling through patient records which would require permission and exceed the appropriate time limit.

As a teaching hospital, we conduct education and research to improve healthcare for our patients. During your visit students may be involved in your care, or you may be asked to participate in a clinical trial. Please speak to your doctor or nurse if you have any concerns. Chief Executive: Joe Harrison Chairman: Simon Lloyd You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom Of Information Co-ordinator For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.